Alpha 2.0
Login Register
» Articles » PMID: 35245082

Granulocyte Colony-Stimulating Factor Usage in Recipients of Chimeric Antigen Receptor T-Cell Immunotherapy

Overview
Journal J Clin Oncol
Specialty Oncology
Date 2022 Mar 4
PMID 35245082
Authors
Muhammad Bilal Abid
Affiliations
Soon will be listed here.
Citing Articles

Recommendations for the effective use of T-cell-redirecting therapies: a Canadian consensus statement.

Lancman G, Song K, White D, Crosbie T, Sharif I, Emond M Front Oncol. 2024; 14:1446995.

PMID: 39659785 PMC: 11628543. DOI: 10.3389/fonc.2024.1446995.

Granulocyte colony-stimulating factor in neutropenia management after CAR-T cell therapy: A safety and efficacy evaluation in refractory/relapsed B-cell acute lymphoblastic leukemia.

Cao X, Zhang M, Guo R, Zhang X, Sun R, Xiao X Chin Med J (Engl). 2024; 138(1):111-113.

PMID: 39658252 PMC: 11717506. DOI: 10.1097/CM9.0000000000003353.

High pretreatment disease burden as a risk factor for infectious complications following CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma.

OReilly M, Neill L, Collin S, Stone N, Springell D, Mensah J Hemasphere. 2024; 8(1):e29.

PMID: 38434533 PMC: 10878197. DOI: 10.1002/hem3.29.

Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma.

Miller K, Johnson P, Abramson J, Soumerai J, Yee A, Branagan A Blood Cancer J. 2022; 12(10):146.

PMID: 36316312 PMC: 9622902. DOI: 10.1038/s41408-022-00741-2.